Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials." by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 70-72

  Costedoat Chalumeau, Nathalie ^b   Izmirly, Peter ^a   Wahren Herlenius, Marie ^c   Silverman, Earl ^d   Brucato, Antonio ^e   Boutjdir, Mohamed ^a   Khamashta, Munther ^f   Llanos, Carolina ^g   Pisoni, Cecilia N ^h   Friedman, Deborah M ⁱ   Clancy, Robert ^a   Phoon, Colin K L ^a   Saxena, Amit ^a   Buyon, Jill P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HÔpital Cochin   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^h CEMIC   (Argentina)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LA ANTIBODY; RO ANTIBODY; TOLL LIKE RECEPTOR;

APOPTOSIS; ATRIOVENTRICULAR BLOCK; AUTOIMMUNITY; CELL INFILTRATION; CONGENITAL HEART BLOCK; CONGENITAL NEONATAL HEART BLOCK; ECHOCARDIOGRAPHY; HEALTH CARE QUALITY; HEART MUSCLE CELL; HUMAN; LETTER; MOTHER; NEWBORN DISEASE; PATHOGENESIS; PHENOTYPE; RECURRENCE RISK; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; HEART BLOCK; HUMANS; MOTHERS;

EID: 84886946538     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.08.003     Document Type: Letter

References (50)

1. Gleicher N., Elkayam U. Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials. Autoimmun Rev 2013, 12:1039-1045.
2. Ambrosi A., Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther 2012, 14:208.
3. Izmirly P.M., Buyon J.P., Saxena A. Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol 2012, 24:466-472.
4. Buyon JP, Friedman DM Neonatal lupus. Systemic lupus erythematosus 2010, 541-571. Elsevier. 5th ed. R.G. Lahita, G. Tsokos, J.P. Buyon, T. Koike (Eds.).
5. Lafyatis R., York M., Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors?. Arthritis Rheum 2006, 54:3068-3070.
6. Rivera T.L., Izmirly P.M., Birnbaum B.K., Byrne P., Brauth J.B., Katholi M., et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009, 68:828-835.
7. Waltuck J., Buyon J.P. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994, 120:544-551.
8. Brucato A., Frassi M., Franceschini F., Cimaz R., Faden D., Pisoni M.P., et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001, 44:1832-1835.
9. Izmirly P.M., Saxena A., Kim M.Y., Wang D., Sahl S.K., Llanos C., et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011, 124:1927-1935.
10. Press J., Uziel Y., Laxer R.M., Luy L., Hamilton R.M., Silverman E.D. Long-term outcome of mothers of children with complete congenital heart block. Am J Med 1996, 100:328-332.
11. Julkunen H., Eronen M. Long-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001, 44:647-652.
12. Garcia S., Nascimento J.H., Bonfa E., Levy R., Oliveira S.F., Tavares A.V., et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994, 93:718-724.
13. Ambrosi A., Dzikaite V., Park J., Strandberg L., Kuchroo V.K., Herlenius E., et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200-239, but not other Ro52 epitopes, induce congenital heart block in a rat model. Ann Rheum Dis 2012, 71:448-454.
14. Boutjdir M., Chen L., Zhang Z.H., Tseng C.E., DiDonato F., Rashbaum W., et al. Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 1997, 80:354-362.
15. Boutjdir M., Chen L., Zhang Z.H., Tseng C.E., El-Sherif N., Buyon J.P. Serum and immunoglobulin G from the mother of a child with congenital heart block induce conduction abnormalities and inhibit L-type calcium channels in a rat heart model. Pediatr Res 1998, 44:11-19.
16. Suzuki H., Silverman E.D., Wu X., Borges C., Zhao S., Isacovics B., et al. Effect of maternal autoantibodies on fetal cardiac conduction: an experimental murine model. Pediatr Res 2005, 57:557-562.
17. Salomonsson S., Sonesson S.E., Ottosson L., Muhallab S., Olsson T., Sunnerhagen M., et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005, 201:11-17.
18. Clancy R.M., Neufing P.J., Zheng P., O'Mahony M., Nimmerjahn F., Gordon T.P., et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006, 116:2413-2422.
19. Jaeggi E.T., Hornberger L.K., Smallhorn J.F., Fouron J.C. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol 2005, 26:16-21.
20. Jaeggi E.T., Hamilton R.M., Silverman E.D., Zamora S.A., Hornberger L.K. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30years. J Am Coll Cardiol 2002, 39:130-137.
21. Villain E., Costedoat-Chalumeau N., Marijon E., Boudjemline Y., Piette J.C., Bonnet D. Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status. J Am Coll Cardiol 2006, 48:1682-1687.
22. Julkunen H., Miettinen A., Walle T.K., Chan E.K., Eronen M. Autoimmune response in mothers of children with congenital and postnatally diagnosed isolated heart block: a population based study. J Rheumatol 2004, 31:183-189.
23. Ambrosi A., Salomonsson S., Eliasson H., Zeffer E., Skog A., Dzikaite V., et al. Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Ann Rheum Dis 2012, 71:334-340.
24. Tunks R.D., Clowse M.E., Miller S.G., Brancazio LR Barker P.C. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol 2013, 208:64 e1-7.
25. Cimaz R., Spence D.L., Hornberger L., Silverman E.D. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003, 142:678-683.
26. Costedoat-Chalumeau N., Amoura Z., Lupoglazoff J.M., Huong D.L., Denjoy I., Vauthier D., et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004, 50:3187-3194.
27. Gerosa M., Cimaz R., Stramba-Badiale M., Goulene K., Meregalli E., Trespidi L., et al. Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases-a multicentre prospective study. Rheumatology (Oxford) 2007, 46:1285-1289.
28. Motta M., Rodriguez-Perez C., Tincani A., Lojacono A., Chirico G. Outcome of infants from mothers with anti-SSA/Ro antibodies. J Perinatol 2007, 27:278-283.
29. Llanos C., Izmirly P.M., Katholi M., Clancy R.M., Friedman D.M., Kim M.Y., et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009, 60:3091-3097.
30. Brucato A., Grava C., Bortolati M., Ikeda K., Milanesi O., Cimaz R., et al. Congenital heart block not associated with anti-Ro/La antibodies: comparison with anti-Ro/La-positive cases. J Rheumatol 2009, 36:1744-1748.
31. Clancy R.M., Kapur R.P., Molad Y., Askanase A.D., Buyon J.P. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004, 50:173-182.
32. Sonesson S.E., Salomonsson S., Jacobsson L.A., Bremme K., Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004, 50:1253-1261.
33. Friedman D.M., Kim M.Y., Copel J.A., Davis C., Phoon C.K., Glickstein J.S., et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008, 117:485-493.
34. Saleeb S., Copel J., Friedman D., Buyon J.P. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999, 42:2335-2345.
35. Theander E., Brucato A., Gudmundsson S., Salomonsson S., Wahren-Herlenius M., Manthorpe R. Primary Sjogren's syndrome-treatment of fetal incomplete atrioventricular block with dexamethasone. J Rheumatol 2001, 28:373-376.
36. Rein A.J., Mevorach D., Perles Z., Gavri S., Nadjari M., Nir A., et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009, 119:1867-1872.
37. Hutter D., Silverman E.D., Jaeggi E.T. The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro/SSA antibodies: a review. Scand J Immunol 2010, 72:235-241.
38. Costedoat-Chalumeau N., Amoura Z., Le Thi Hong D., Wechsler B., Vauthier D., Ghillani P., et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003, 62:1010-1012.
39. Friedman D.M., Llanos C., Izmirly P.M., Brock B., Byron J., Copel J., et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010, 62:1138-1146.
40. Pisoni C.N., Brucato A., Ruffatti A., Espinosa G., Cervera R., Belmonte-Serrano M., et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010, 62:1147-1152.
41. Izmirly P.M., Kim M.Y., Llanos C., Le P.U., Guerra M.M., Askanase A.D., et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010, 69:1827-1830.
42. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C.N., Khamashta M.A., Kim M.Y., Saxena A., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012, 126:76-82.
43. Siren M.K., Julkunen H., Kaaja R. The increasing incidence of isolated congenital heart block in Finland. J Rheumatol 1998, 25:1862-1864.
44. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
45. Costedoat-Chalumeau N., Amoura Z., Huong D.L., Lechat P., Piette J.C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005, 4:111-115.
46. Diav-Citrin O., Blyakhman S., Shechtman S., Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 2013, 39C:58-62.
47. Osadchy A., Ratnapalan T., Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011, 38:2504-2508.
48. Clowse M.E., Magder L., Witter F., Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54:3640-3647.
49. Levy R.A., Vilela V.S., Cataldo M.J., Ramos R.C., Duarte J.L., Tura B.R., et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001, 10:401-404.
50. Ostensen M., Brucato A., Carp H., Chambers C., Dolhain R.J., Doria A., et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford) 2011, 50:657-664.